

皮膚感作性試験代替法の現状

小島 肇夫

Hajime Kojima

国立医薬品食品衛生研究所 安全性生物試験研究センター 薬理部

▼ 1. なぜ動物実験代替法が必要か？

欧州における化学物質の安全性再評価 (REACH: Registration, Evaluation and Authorization of CHemicals)¹⁾ および化粧品の製造・販売に動物実験を用いないという 2009 年と 2013 年に施行される予定の化粧品規制により²⁾, 動物実験代替法(代替法)を巡る議論が欧米では盛んである。日本では他人事のように捉えられているが、経済のグローバル化を考えると、欧州の規制に従わない化学物質や化粧品は少なくとも欧州では販売できない、欧州から輸入される化学物質や薬用化粧品(医薬部外品)は日本の規制に合わず売れないことにより、経済的損失も大きくなり傍観しているわけにはいかない。

このような状況から、皮膚の安全性評価でもっとも大きなウエイトを占める皮膚感作性についても代替法の開発が盛んである。具体的には、既存のモルモットを用い

た動物実験に代わりうる、後述するマウスを用いた Local Lymph node Assay (LLNA) を *in silico* (コンピュータを用いた手法) や *in vitro* 試験に置き換えるための検討が国際的に進んでいる。

ただし、すでに開発された方法が多数あったとしても、ことはそう簡単ではない。たとえば、これまで汎用されているモルモットを用いる Maximization test や Buehler test を新しい感作性試験の代替法に置き換え、安全性が担保できるか検証するためには、図 1 に示すように³⁾, バリデーションや専門家による第三者評価、行政的な受け入れのための評価という何段階にもわたるチェックが必要である。これは 2005 年に認証された OECD ガイダンス文書 34 に定められており⁴⁾, この過程を経ないと公的な試験法として国際的に認められない。

これに対応する部署として、筆者が室長を務める新規試験法評価室が国立医薬品食品衛生研究所 安全性生物試験研究センター 薬理部内に 2005 年 11 月に設立された⁵⁻⁷⁾, この部署の業務の一つが新規代替法のバリデーションと第三者評価であり、この活動を JaCVAM (Japanese Center for the Validation of Alternative Methods) と名づけている。

〒158-8501 東京都世田谷区上用賀 1-18-1

E-mail: h-kojima@nihs.go.jp

図1 試験法バリデーションのプロセス³⁾

2. 感作性試験代替法 LLNA

さて、以上の国際的な潮流を念頭に、本章のタイトルである感作性試験代替法の現状として、まずLLNAについて触れておきたい。

2002年、モルモットを用いる方法に代わり、LLNAがOECDガイドライン429として認証された⁸⁾。この方法は動物の完全置き換えができた代替法ではないが、中動物から小動物へ動物種を変更、動物数の削減が可能になった動物実験の3Rs (Reduction, Refinement, Replacement)のうち、ReductionやRefinementを可能にした試験方法である。感作性の成立までの複雑なシステムをリンパ球の増殖で補うという実験規模と実験期間を短縮した試験法である。ただし、トリチウムチミジンの取り込みを評価指標とするため、日本では実験できる施設が限られ、普及度は高くなかった。そこで、放射性物質を使わない方法の検討が進んでいる。

たとえば、日本ではダイセル化学工業(株)によりATPの取り込みを指標としたLLNA-DA法が開発され⁹⁾、すでにバリデーション研究が終了して、専門家による第三者評価が進んでいる¹⁰⁾。BrdUの取り込みを指標としたLLNA-BrdU法も(財)化学物質評価研究機構によって開発され、日本動物実験代替法学会にてバリデーション研究が実施されている。

欧米では、規制に用いるための予測性の検証や^{11~13)}、放射性物質を用いない試験法の開発はもちろんのこと、改良試験法の追加バリデーションを実施するための試験

法基準の作成が議論されており、日本のバリデーションにも影響を及ぼしている。さらに、動物数を削減するため、1濃度のみで試験を行うreduced LLNAについても検討が進んでいる¹⁴⁾。欧州ではこの方法がREACHのためにスクリーニングとして認められている。以上のようなLLNAを巡る動向は2007~2008年にかけて活発に議論されている。

ところで、安全性評価はhazard identification (有害性の同定)とrisk assessment (リスク評価)とに大別されており、リスク評価は有害性の同定、用量反応性、曝露評価などを合わせてなされる¹⁵⁾。従来のモルモットを用いるBuehler assayにおいてはリスク評価が可能であったが、reduced LLNAでは有害性の同定しかできない。LLNAでは用量反応性が捉えられるが、曝露評価、感作性の成立まで考慮に入れた研究や議論がもっとなされなければならない。ともかく、規制当局がモルモットの試験結果を採用しなれば、LLNAだけで新たな医薬品や農薬の開発に支障を来さないことを示す検討を必要とする。

化粧品の場合はまず安全性ありきの製品であることから、有害性の同定を第一に考えればよいかもしれない。よって、LLNAの導入に異論はない。後述する動物実験を用いない試験法でも公式に認められれば置き換えていけばよいと考えている。ただし、医薬品や農薬の場合にはリスク評価と薬効を天秤に掛けねばならないことから、LLNAによるリスク評価が不完全な場合、Human Repeated Insult Test (HPIT)のようなヒトによる連続適用試験が確認試験でなく、リスク評価に用いられることになる。これはボランティアの人権、倫理的な面からみて許されるものではない。真の実用化にはまだ課題も多い。

3. In vitro 感作性試験の開発

さて、どの試験法もバリデーションが実施されておらず、すでに2009年には間に合わないが、2013年の化粧品規制までの設立を目指しているin silicoおよびin vitro感作性試験代替法の現状に触れておきたい。

代替法としては、①in silicoにおける評価、②in vitro試験としてペプチド結合試験、③培養細胞を用いる試験、④培養皮膚モデルを用いる試験に大別される。これらは図2に示すような、感作誘導に重要な作用機構に立脚した試験法であり、動物を使わないで評価する




図2 アレルギー性接触皮膚炎の感作誘導における重要な作用機構

ならば、これらの試験を組み合わせたスキームの構築が重要であると考えている^{16, 17)}。

① *in silico*

感作性物質の構造活性部位はほぼ明らかになってきており、専門家であれば、構造をみればある程度の感作の有無を予測できよう。Aptulaらはこれを統計学的手法などによって検討を行い¹⁸⁾、Ensleinらもデータベースを活かして感作性強度を判断してきた¹⁹⁾。これらの文献を数値化したソフト(DEREK²⁰⁾やTOPKAT²¹⁾などが多数販売されており、かなりの精度で感作性の強度予測が可能である。ただし、データベース数(ヒトやモルモットの結果が揃っているデータ)がこれ以上増える可能性が低いこと、すべての化学物質が純品でなく、不純物が感作性を示す場合もあり、ここで陰性の結果を得たからといって以下の試験を省略できるわけではない。あくまでも有用な第一次スクリーニングである。

② ペプチド結合試験

感作性物質がハプテンに結合すること、特定のアミノ酸構造に結合することを利用して、ペプチド、とくにシステインをもつグルタチオンや合成ペプチドとの結合による挙動の変化をHPLC(高速液体クロマトグラフィ)で測定するものである。Katoら²²⁾、Gerberickら²³⁾、中村²⁴⁾の検討がなされている。Gerberickらの検討によれば²⁵⁾、システインやリジンペプチドとの反応性で得られた結果とLLNAの一致率は89%であり、4段階の強度分類も可能とされており、スクリーニング法として有用であるとされている。

③ 培養細胞を用いる試験

皮膚のなかで最初に感作性物質に曝露させる細胞はケラチノサイトである。皮膚に浸透された感作性物質はハプテンとしてケラチノサイトに結合し、サイトカインやケモカインを産生して感作源となる。ケラチノサイトを用いた感作性のスクリーニングはVandebrielらの検討があるが、あまり多くない^{26, 27)}。

むしろ、アレルギーといえはランゲルハンス細胞の挙動であろう。以前から、ランゲルハンス細胞の活性に着目した検討がなされたが^{28, 29)}、試験法を開発するうえで十分な細胞を確保できないという課題があった³⁰⁾。そこで、ランゲルハンス細胞起源であるヒト末梢血や臍帯血の細胞を樹状細胞に分化させる方法が検討されてきた。バイオマーカーとしては、MHC Class II、CD86などの表面抗原³¹⁻³³⁾、TNF- α ³⁴⁾、IL-1 β ³⁵⁾、IL-8³⁶⁾などのサイトカイン、CXCR4³⁷⁾、CCR7³⁸⁾、CCL2³⁹⁾などのケモカインおよびケモカインレセプターなどが報告されている。

しかし、細胞誘導に時間を要することや経費の問題などに加え、同一ドナーから入手できる細胞数に限界があり、かつドナー間の反応性に相違があることから、試験法の構築には支障が大きかった^{31, 35, 40)}。そこで、安定供給や個体差のない単球系の細胞株(CD14陽性のTHP-1細胞^{33, 41)}、U937細胞^{42, 43)}、CD34陽性のKG-1細胞⁴⁴⁾、MUTZ-3細胞⁴⁵⁾など)を用いた検討が主流となっている。

これらのなかで、資生堂と花王のグループがTHP-1細胞に着目し、その表面抗原のなかで、CD86およびCD54の変化を指標とした試験法を確立した^{46, 47)}。この試験法は96 wellプレートを用いてフローサイトメトリーで解析を行う簡便な方法であり、ヒト細胞株活性化試験(human Cell Line Activation Test: h-CLAT)と命名されている。2施設間の比較試験では、高い一致性が報告されており、LLNAとの一致率も62物質で90%ときわめて高い。そこで、厚生労働科学研究の支援を受けた化粧品企業や欧州化粧品工業会との間で共同研究が実施され、技術移転の容易性や施設間再現性が検討されている状況である。本試験方法はバリデーションに移行すべき段階に来ていると考えられる。

④ 培養皮膚モデルを用いる試験

Coquetteらは、3次元培養表皮モデルに感作性物質を適用して、ケラチノサイトの放出するIL-1 α やIL-8

皮膚感作性試験代替法の現状

を調べ、感作性物質と IL-8 の関係を報告している⁴⁸⁾。

また、樹状細胞を導入した3次元培養表皮モデルによる感作性物質の挙動の報告もある^{49)・50)}。ランゲルハンス細胞の培養がむずかしく、免疫担当細胞を導入したモデルの開発は進んでいなかったが、幹細胞研究やヒト細胞の利用が進む昨今、このモデルの研究がより進むと考えられる。h-CLATなどのヒト樹状細胞株を用いたこれまでの成果が本モデルの構築に反映されれば、より精度の高いモデルの開発が期待される。本モデルは、種々の濃度や製剤の形態で感作性物質を適用し、その後のサイトカインやケモカインの挙動を検索できるという点で用量反応性や曝露評価に利用できる可能性が高く、リスク評価モデルとして期待されている。

▼ おわりに

JaCVAMの立場は欧米との国際協調を重視して新規の動物実験代替法を確立することである。これはグローバル化が進む昨今、避けては通れない課題である。だからといって、化粧品や化学物質の安全性評価の質を下げるべきではない。安全性の担保が第一優先である。昔のような化粧品による黒皮症を再燃させるわけにはいかない。黒皮症は原因究明に当たられた皮膚科医の努力と⁵¹⁾、その後行政や業界が導入したモルモットを用いた試験法により激減したわけであり⁵²⁾、この安全性の質を担保しなければならない。安全性を担保しながら代替法の国際協調を進める。“出口があっても実はないかもしれない”この問題を解く鍵は、「これまでにない技術」による新試験法の開発であると信じている。そのためには、基礎研究の充実が欠かせない。専門家の研究から素晴らしい成果が得られることを期待してやまない。

文献

- 1) <http://ecb.jrc.ir/REACH/>
- 2) Commission Staff Working Documents: Time Tables for the phasing-out of animal testing in the framework of the 7th Amendment to the Cosmetics Directive: EN, SEC82004, 1210, 2004
- 3) ICCVAM (1997) : Validation and regulatory acceptance of toxicological test methods: a report of the *ad hoc* Inter-agency Coordinating Committee on the Validation of Alternative Methods. NIH Publication No: 97-3981, 1997, National Institute of Environmental Health Sciences (NIEHS)
- 4) OECD (2005) : OECD Series on testing and assessment Number 34, Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment, ENJ/JM/MONO (2005), 14, 2005
- 5) 大野泰雄: フレグランスジャーナル 293: 30, 2005
- 6) 小島肇夫: 日本化粧品技術者会誌 40: 263, 2006
- 7) 小島肇夫: 日皮協ジャーナル 57: 129, 2007
- 8) OECD Guideline 429: Skin Sensitization: Local Lymph Node Assay. OECD Guideline for the Testing of Chemicals. Paris, 2002
- 9) Yamashita K et al: Altern Animal Test Experiment 11 (2) : 136, 2005
- 10) Takeyoshi M et al: Toxicol Lett 119: 203, 2001
- 11) Cockshott A et al: Hum Exp Toxicol 25: 387, 2006
- 12) McGarry HF: Toxicology 238: 71, 2007
- 13) Basketter DA, Kimber I: Contact Dermatitis 56: 1, 2007
- 14) <http://ecvam.jrc.cec.eu.int/index.htm>
- 15) 山本 郁: ファルマシア 40: 215, 2004
- 16) Ryan CA, Hulette BC, Gerberick GF: Toxicol In Vitro 15: 43, 2001
- 17) 小島肇夫: 化粧品大全, 情報機構, 東京, p.407, 2006
- 18) Aptula AO, Patlwiez G, Roberts DW: Chem Res Toxicol 18: 1420, 2005
- 19) Enslein K et al: Food Chem Toxicol 35: 1091, 1997
- 20) Sanderson DM, Earnshaw CG: Hum Exp Toxicol 10: 261, 1991
- 21) Enslein K, Gombar VK, Blake BW: Mutat Res 305: 47, 1994
- 22) Kato H et al: J Toxicol Sci 28: 19, 2003
- 23) Gerberick GF et al: Toxicol Sci 81: 332, 2004
- 24) 中村洋介: 最新動物実験代替法, 技術情報協会, 東京, p.130, 2007
- 25) Gerberick GF et al: Toxicol Sci 97: 417, 2007
- 26) Vandebriel RJ, van Och FM, van Loveren H: Toxicol Appl Pharmacol 207: 142, 2005
- 27) van Och FM et al: Toxicology 210: 95, 2005
- 28) Herouet C et al: Eur J Dermatol 9: 185, 1999
- 29) Rizova H et al: Br J Dermatol 140: 200, 1999
- 30) Basketter D et al: Altern Lab Anim 33: 83, 2005
- 31) Aiba S et al: Eur J Immunol 27: 3031, 1997
- 32) De Smedt AC et al: Arch Dermatol Res 294: 109, 2002
- 33) Ashikaga T et al: Toxicol In Vitro 16: 711, 2002
- 34) Coutant KD et al: Toxicol Sci 52: 189, 1999
- 35) Pichowski JS et al: Toxicol In Vitro 14: 351, 2000
- 36) Toebak MJ et al: Toxicol In Vitro 20: 117, 2006
- 37) Rustemeyer T et al: Exp Dermatol 12: 682, 2003
- 38) Boislève F et al: J Invest Dermatol 123: 494, 2004
- 39) Verheyen GR et al: Toxicol Lett 155: 187, 2005
- 40) Ryan CA et al: Toxicol Appl Pharmacol 221: 384, 2007
- 41) Yoshida Y et al: Toxicol In Vitro 17: 221, 2003
- 42) Sakaguchi H et al: Toxicol In Vitro 20: 774, 2006
- 43) von Blomberg-van der Flier M et al: J Invest Dermatol 88: 362, 1987
- 44) Hulette BC et al: Arch Dermatol Res 293: 147, 2001
- 45) Azam P et al: Toxicol Appl Pharmacol 212: 14, 2006
- 46) Ashikaga T et al: Toxicol In Vitro 20: 767, 2006
- 47) Sakaguchi H et al: Arch Dermatol Res 298: 427, 2007
- 48) Coquette A et al: Toxicol In Vitro 17: 311, 2003
- 49) Facy V et al: J Invest Dermatol 122: 552, 2004
- 50) Jacobs JJ et al: Exp Dermatol 15: 432, 2006
- 51) 小塚雄民, 高瀬吉雄: 皮膚と化粧品科学, 南山堂, 東京, p.267, 1982
- 52) 日本化粧品工業連合会編: 安全性評価に関する指針 2001, 薬事日報社, 東京, p.1, 2001

Perspectives on Validation and Regulatory Acceptance of Animal Alternative Testings in Japan

Hajime Kojima, Japanese Center for the Validation of Alternative Methods (JaCVAM), National Institute of Health Sciences (NIHS), Japan

From the Editor

Recent scientific advancement in understanding of toxic mechanisms enables risk assessors to develop new and revised toxicological test methods that better predict potential toxic effects of chemicals. In this issue, we update current status of research activities in the development of animal alternative methods that may refine, reduce, or replace animal use for toxicity testing. Contributors to this issue include Dr. Kojima at NIHS, Japan, and Dr. Scott Belanger, environmental toxicologist and Dr. Pauline McNamee, human safety toxicologist at P&G.

Seok (Soga) Kwon, Ph.D.

Inside this issue:

Animal Alternatives Needs in Environmental Sciences 5

In Vitro Methods for Eye Irritation 7

In November 2005, Japanese Center for the Validation of Alternative Methods (JaCVAM) was established in the Division of Pharmacology at the National Center for Biological Safety and Research affiliated to National Institute of Health Sciences (NIHS) in Japan. JaCVAM facilitates the validation, peer-review, and international harmonization of alternative methods. Key objectives of JaCVAM are: 1) to facilitate 3R's* with Reduction and Replacement prioritized and 2) to ensure new test methods are validated, peer reviewed, officially accepted by the regulatory agencies, and internationally harmonized. JaCVAM has its own steering committee which is in charge of JaCVAM activities. JaCVAM facilitates validation studies and peer-review process for new methods. JaCVAM also proposes a validated method to the regulatory agencies for their acceptance.

JaCVAM's current activities and future directions on the validation and peer review of alternative to animal testings will be discussed in this paper. JaCVAM plays an important role in evaluating alternative test methods to be used in the safety assessment of cosmetic products. A new EU directive prohibiting *in vivo* tests on cosmetic ingredients (the 7th Amendment, Council Directive 2003/15/EC)¹⁾ also engaged JaCVAM to actively support the validation of test methods.

The major activities of JaCVAM include:

- 1) Coordinate the technical evaluation and regulatory acceptance of new and revised test methods
- 2) Delegate validation work for new and revised test methods
- 3) Promote 3R's and facilitate international harmonization of alternative to animal testings

JaCVAM is currently coordinating validation studies and peer-review for several test methods (shown in Table 1). Most of the test methods are to be used in the safety assessment of cosmetic products. In Japan, there is a unique cosmetic product category called "Quasi-Drug (QD)" which requires pre-market registration approved by Japan government prior to their introduction to markets. Thus, JaCVAM is also involved in the

*3R's : Refinement, Reduction, Replacement

technical review of the overall safety evaluation process for QD products, which utilizes alternative test methods. In 2007, a new committee called "Review committee on the safety assessment for QD products" was established with participation of representatives including dermatologists, experts from cosmetic industries and Japanese Society for Alternatives to Animal Experiments (JSAAE). This committee is conducting a 3-year research project funded by Ministry of Health, Labor, and Welfare (MHLW) to provide technical guidance on the safety evaluation of QD products. The project progress is to be updated in 2009 when the 7th Amendment in EU becomes effective. Specific activities on the validation of alternative test methods on major toxicity endpoints related to cosmetic products in Japan will be discussed.

1) Skin Irritation

In April 2007, the European Center for the Validation of Alternative Methods (ECVAM) Scientific Advisory Committee [ESAC] endorsed the EPISKIN method employing cultured epidermis models (EPISKINTM)²⁾. This endorsement triggered Japanese researchers to accelerate their validation activities. Japanese researchers have been using commercially available cultured skin/epidermis models such as TESTSKINTM (Toyobo), Vitrolife-SkinTM (Gunze), and EpiDermTM (MatTek and Kurabo). Pre-validation studies have been completed for these models with favorable results³⁾.

TESTSKINTM model⁴⁾ and Vitrolife-SkinTM model⁵⁻⁶⁾ were further assessed for validation studies to be considered as alternative test methods for predicting skin irritation of cosmetic ingredients at their usage levels. These two skin models successfully completed validation studies. The results showed that their predictive capability of skin irritation is equivalent to those of Human Patch Test (HPT) and *in vivo* primary skin irritation test. However, these methods have not completed the peer-review process in Japan. Japanese manufacturers are planning to validate the Japanese skin models in the spring of 2008 by employing reference substances used by EU for the EPISKINTM and currently seeking technical collaboration with JSAAE.

2) Eye Irritation

In 1998, the guidance for alternative methods on eye irritation utilizing a cytotoxicity method⁷⁾ was established⁸⁾. This work was funded by MHLW. However, this guidance has not been widely utilized in Japan. For example, this guidance was not referred in "Questions and Answers (Q&A) attached to the QD manufacturing and marketing approval application and cosmetics criteria amendment request" issued in 2006⁹⁾. This suggests that the cytotoxicity method has not been recognized as a validated alternative test method by the regulatory agencies. Therefore, JaCVAM is to conduct the technical evaluation of a cytotoxicity method by reviewing validation study results generated by

Toxicological endpoint	Test methods	Current activities
Phototoxicity	Testing Battery (Yeast-RBC): Yeast Growth Inhibition Phototoxicity Assay Red Blood Cell Photochemolysis Assay	Peer review in progress
	Local Lymph Node Assay using ATP contact measurement (LLNA-DA)	Peer review in progress
	Local Lymph Node Assay using BrdU uptake measurement (LLNA-BrdU)	Validation in progress
Skin sensitization	Human Cell Line Activation Test (h-CLAT)	Planning
	Culture model	Regulatory acceptance in progress
Corrosiveness	Culture model	Planning on peer review
Skin irritation	Lumi-cell, CER-estrogen reporter assay	Validation in progress
Endocrine disrupter	Comet assay (<i>in vivo</i> or <i>in vitro</i>)	Validation in progress
Mutagenicity		

Table 1. Current status of validation and peer review for animal alternative methods coordinated by JaCVAM

JSAAE, MHLW Scientific Research, EU and USA. In EU and USA, however, the review panels have completed the peer-review process for Isolated Eye Test methods, Isolated Corneal Test method, and Hen's Egg Test¹⁰. And the panels concluded that these methods could be used for screening purpose. JaCVAM is also planning to conduct the peer-review of these test methods.

3) Phototoxicity

In vitro 3T3 Neutral Red Uptake (NRU) phototoxicity test has been peer reviewed and accepted as a reliable alternative method in Japan¹¹. This method had been previously adopted by OECD¹². On the other hand, Shiseido developed a test battery including Yeast Membrane Disruption assay and Red Blood Cell Hemolysis test¹³⁻¹⁵. At Shiseido's request, a review committee of MHLW Scientific Research assessed the validity of these test methods. The test methods were further refined in response to results of the initial validation, and they have undergone the 2nd validation process. The peer-review of these methods is in progress and their regulatory acceptance will be assessed in 2008.

4) Skin Sensitization

The Local Lymph Node Assay (LLNA) can be used as an alternative method because it has been already adopted by OECD¹⁶. However, the use of radioisotopes (RI) limits the practical application of LLNA by Japanese laboratories. Thus, other methods involving no RI are currently under the validation process. They include LLNA-DA method (ATP content index)¹⁷ and LLNA-BrdU method (BrdU uptake index)¹⁸. The LLNA-DA method showed favorable results of validation studies and was further progressed to the peer review process. The LLNA-BrdU method is in the process of 2nd validation with protocol modification in response to the 1st validation. In future, these test methods are expected to be widely utilized in Japan. New test methods are also continuously being developed for the safety assessment of cosmetic products because LLNA still requires animal use. Therefore, Shiseido and Kao developed h-CLAT (human Cell Line Activation Test) method^{19,20} in collaboration with industry associations such as Japan Cosmetic Industry Association (JCIA) and the European Cosmetic Toiletry and Perfumery Association (COLIPA). The scientific validation for this test method is expected to occur. The Structural Activity Relationships (SAR)

analysis could be used for predicting skin sensitization in future considering significant technical advancement in computer modeling areas. In addition to h-CLAT method, other new test methods are also being developed. They include peptide binding assay and cell culture methods. JaCVAM will coordinate validation studies and peer-review of these new test methods.

This paper described current status and future directions of the validation and regulatory acceptance of alternative to animal testings focusing on major toxicity endpoints related to cosmetic products in Japan. JaCVAM also coordinates technical evaluation of alternative methods for other toxicological endpoints such as acute toxicity and mutagenicity. Detailed information on these endpoints will be discussed in future. In collaboration with international organizations, significant progress has been made in the validation of alternative methods. JaCVAM's mission is to facilitate the validation of alternative methods while domestically developed test methods are prioritized.

Acknowledgments

We thank Ms. Sanae Takeuchi at P&G for her help in preparation for the manuscript.

References

1. Commission Staff Working Documents; Timetables for the phasing-out of animal testing in the framework of the 7th Amendment to the Cosmetics Directive (Council Directive 76/768/EEC); Commission of the European Communities, SEC(2004)1210, (2004).
2. Statement on the Validity of *In Vitro* Tests for Skin Irritation, ESAC statement, (2007).
3. Sonoda, I., et al. (2002) A prevalidation study for three-dimensional culture human skin models as alternatives to skin irritation testing. *Altern. Animal Test. Experiment*, 8: 91-106.
4. Kojima, H., et al. (2005) Validation study for TESTSKINTM, a three-dimensional cultured human skin model, as alternatives to skin irritation testing applied to forty cosmetic substances, The Fifth World Congress on Alternative and Animal Use in the Life Science, Berlin.
5. Kojima, H., et al. (2005) Validation study for Vitrolife-SkinTM, a three-dimensional cultured human skin model, I, as an alternative to skin irritation

testing using ET₅₀ protocol, The Fifth World Congress on Alternative and Animal Use in the Life Science, Berlin.

6.Kojima, H., et al. (2005) Validation study for Vitrolife-Skin™, a three-dimensional cultured human skin model, II, as a alternative to skin irritation testing using Post-Incubation (PI) protocol, The Fifth World Congress on Alternative and Animal Use in the Life Science, Berlin.

7.Ohno, Y. (1990) Interlaboratory validation of the *in vitro* eye irritation tests for cosmetic ingredients. (1) Overview of the validation study and Draize scores for the evaluation of the tests. *Toxicology in Vitro*, 13(1): 73-98.

8.Ohno, Y. (1999) Guidance for evaluation of eye irritation and alternatives to Draize tests for cosmetics. *Fragrance Journal*, 27(7): 21-26.

9.Questions and Answers (Q&A) attached to the QD manufacturing and marketing approval application and cosmetics criteria amendment request. (2004) Evaluation and licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, Japan.

10.Expert Panel Report: *In Vitro* Ocular Toxicity Test Methods for Identifying Severe Irritants and Corrosives, ICCVAM/NICEATM (2005).

11.Ohno, Y., et al. (2004) Pilot study of the evaluation of alternative toxicity tests. Evaluation of 3T3-NRU phototoxicity tests. *Altern. Animal Test. Experiment*, 10(2), 50-142.

12.Test No. 432 *In Vitro* 3T3 NRU phototoxicity test, OECD Guidelines for the Testing of Chemicals – Sections 4: Health Effects (2004).

13.Sugiyama, M., et al. (1994) *In vitro* assay to predict phototoxicity of chemicals: (I) Red Blood Cell Hemolysis Assay. *Altern. Animal Test. Experiment*, 2(4): 183-191.

14.Sugiyama M., et al. (1994) *In vitro* assay to predict phototoxicity of chemicals: (II) Yeast Growth Inhibition Assay and battery system with Photochemolysis Assay, *Altern. Animal Test. Experiment*, 2(4): 193-202.

15.Mori, M., et al. (2004) Effects of light sources on the prediction of phototoxicity by the Yeast Growth Inhibition Phototoxicity Assay and the Red Blood Cell Photohemolysis Assay. *Altern. Animal Test. Experiment*, 10(1): 1-17.

16.Test No. 432 Skin Sensitization: Local Lymph Node Assay, OECD Guidelines for the Testing of Chemicals – Sections 4: Health Effects (2002).

17.Yamashita, K., et al. (2005) Development of a

modified Local Lymph Node Assay using ATP measurement as an endpoint. *Altern. Animal Test. Experiment*, 11(2): 136-144.

18.Takeyoshi, M., et al. (2001) Development of non-radio isotopic endpoint of murine Local Lymph Node Assay based on 5-bromo-2'-deoxyuridine (BrdU) incorporation. *Toxicol. Lett.* 119(3): 203-208.

19.Ashikaga, T., et al. (2006) Development of an *in vitro* skin sensitization test using human cell lines: The human Cell Line Activation Test (h-CLAT): I. Optimization of the h-CLAT protocol. *Toxicology In Vitro*, 20(5): 767-773.

20.Sakaguchi, H., et al. (2006) Development of an *in vitro* skin sensitization test using human cell lines; human Cell Line Activation Test (h-CLAT) II. An inter-laboratory study of the h-CLAT. *Toxicology In Vitro*, 20(5): 774-784.

ORIGINAL ARTICLE

**Validation of human skin models for
skin corrosivity tests in Japan**

**Hajime Kojima^{1,6}, Tomoko Ando², Katsuhiko Inagaki³,
Mahito Ohhira⁴, Tadashi Kosaka⁵, Yosuke Nakamura⁷,
Hisashi Torishima⁸, Noriyuki Morikawa⁹, Jun Kanno²,
Mami Kuboki⁴, Michiru Genno⁸, Masaru Nokata³,
Takanori Harada⁵, Takashi Morimoto⁷, Isao Yoshimura¹⁰
and Yasuo Ohno¹¹**

¹*Japanese Center for the Validation of Alternative Methods (JaCVAM),
National Institute of Health Sciences (NIHS), Japan,*

²*Div. Cellular and Molecular Toxicol. NIHS, Japan,*

³*Res. & Develop., Div., Product Safety & Pharmaceutical Research Unit, Nihon Nohyaku Co., Ltd., Japan,*

⁴*Toxicol. Res. Dep., ODAWARA Res. Center, Nippon Soda Co., Ltd., Japan,*

⁵*Toxicol. Div. The Inst. Environ. Toxicol., Japan,*

⁶*Res. Lab., Nippon Menard Cosmetic Co., Ltd., Japan,*

⁷*Environ. Health Sci. Lab., Sumitomo Chemical Co., Ltd., Japan,*

⁸*Bio-Medical Dep., Kurabo Industries Ltd., Japan,*

⁹*Div. R&D, Gunze Ltd., Japan,* ¹⁰*Fac. Eng. Tokyo Univ. Science, Japan,* ¹¹*NIHS Japan*

ORIGINAL ARTICLE

Validation of human skin models for skin corrosivity tests in Japan

Hajime Kojima^{1,6}, Tomoko Ando², Katsuhiko Inagaki³,
Mahito Ohhira⁴, Tadashi Kosaka⁵, Yosuke Nakamura⁷,
Hisashi Torishima⁸, Noriyuki Morikawa⁹, Jun Kanno²,
Mami Kuboki⁴, Michiru Genno⁸, Masaru Nokata³,
Takanori Harada⁵, Takashi Morimoto⁷, Isao Yoshimura¹⁰
and Yasuo Ohno¹¹

¹Japanese Center for the Validation of Alternative Methods (JaCVAM),
National Institute of Health Sciences (NIHS), Japan,

²Div. Cellular and Molecular Toxicol. NIHS, Japan,

³Res. & Develop., Div., Product Safety & Pharmaceutical Research Unit, Nihon Nohyaku Co., Ltd., Japan,

⁴Toxicol. Res. Dep., ODAWARA Res. Center, Nippon Soda Co., Ltd., Japan,

⁵Toxicol. Div. The Inst. Environ. Toxicol., Japan,

⁶Res. Lab., Nippon Menard Cosmetic Co., Ltd., Japan,

⁷Environ. Health Sci. Lab., Sumitomo Chemical Co., Ltd., Japan,

⁸Bio-Medical Dep., Kurabo Industries Ltd., Japan,

⁹Div. R&D, Gunze Ltd., Japan, ¹⁰Fac. Eng. Tokyo Univ. Science, Japan, ¹¹NIHS Japan

Abstract

As shown in OECD test guidelines 430 and 431, the human skin epidermal assay and Transcutaneous Electrical Resistance Test (TER) were validated and peer reviewed as an alternative method to corrosivity testing; however, these methods have not been used widely in Japan. The problems related to techniques and evaluation are not clear. Therefore, we performed a validation study of EPI-200 (EpiDerm™), a 3-dimensional cultured epidermal model and Vitrolife-Skin™, a 3-dimensional cultured skin model made in Japan as a catch-up validation trial of alternatives for skin corrosivity testing using 13 chemicals including a positive control: 10% potassium hydroxide solution in Japan. From the obtained data, we identified the potential of utilizing these models to evaluate the corrosivity of a chemical.

Key words: Skin corrosivity, cultured epidermal model, cultured skin model, validation

Introduction

Over the last decade, the European Centre for the Validation of Alternative Methods (ECVAM) has supported formal validation studies using *in vitro* tests as a replacement for the *in vivo* rabbit test for predicting skin corrosivity (Botham, et al., 1995, Barratt, et al., 1998, Fentem et al., 1998, Liebsch et al., 2000). As a result, two new test methods for skin corrosion, which incorporates a rat skin

transcutaneous electrical resistance assay (TER) and two human skin epidermal assays, were included in Annex V of Directive 67/548/EEC in mid-2000, thereby making the use of *in vitro* alternatives for skin corrosivity testing of chemicals mandatory in the European Union (EC, 2000). As human epidermal model assays, two methods based on commercial human epidermal models, EPISKIN™ (EPISKIN, Chaponost, France) and

EpiDerm™ (MatTek, Ashford, MA, USA), were also endorsed.

Meanwhile, the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) in the USA prepared final recommendations on these methods for their consideration and acceptance where appropriate (NIH Publication No.02-4502; ICCVAM, 2002). As a result, these assays were published as an alternative method to corrosivity testing as shown in the OECD test guidelines 430(OECD 430; 2004), and 431(OECD 431; 2004).

In Japan, these methods have not been widely used. The problems related to techniques and evaluation are not clear. In the present study, therefore we performed a catch-up validation trial to evaluate skin corrosivity using the human epidermal and skin models, that is, evaluations were made based on the ECVAM experimental protocol.

We performed a validation study of EPI-200 (EpiDerm™), a 3-dimensional cultured epidermal model and Vitrolife-Skin™, a 3-dimensional cultured skin model as validation trials of alternative for skin corrosivity testing in Japan. From the obtained data, we investigated the possibility of utilizing these models to evaluate the corrosivity of a chemical. We may suggest using these models to the ad hoc. committee of toxicology at MHLW in Japan.

Materials and Methods

Study management and organization

The study was performed according to the Japanese

Society for the Alternative to Animal Testing Experiments (JSAAE) validation scheme as shown in Fig.1. The chairman was Dr. I Yoshimura at the Fac. Eng. Tokyo Univ. Science, who is head of the validation committee in JSAAE. Dr. Ohno at the National Institute of Health Sciences (NIHS) prepared the protocol and supported this validation with a grant from MHLW. Six Laboratories joined the study as shown in Table 1, and a blind trial with 13 chemicals including a positive control (10% potassium hydroxide solution) was performed using the protocol. In addition, Dr. Y. Ohno, the chemical distributor, coded and distributed the test chemicals to be used in the blind trial. After submission of all coded data to biostatisticians, an independent biostatistical analysis of the blind trial was performed at the Fac. Med. Kyoto Univ. and Fac. Eng. Tokyo Univ. Science. The study director at each laboratory, a chemical distributor, biostatisticians and kit suppliers were organized into study management teams in this validation assay as shown in Fig. 1. Finally, the chairman reported the outcome of this validation and forwarded this report to JSAAE.

Technical transfer and preliminary tests

The management team performed the technical transfer by kit suppliers at NIHS, Tokyo on January 28, 2004. After that, technicians performed the preliminary test using 10% potassium hydroxide solution and benzalkonium chloride 10 % solution. A qualified technician from each laboratory participated in the technical transfer and the preliminary





Fig.2 EpiDerm™

Fig.3 Vitrolife-Skin™

test. All technicians obtained good results in this test.

Cultured epidermal and skin models

EpiDerm™ (EPI-200) models were purchased from KURABO Corporation (Osaka, Japan) as kits containing 24 models as shown in Fig.2, with sufficient amounts of Dulbecco's modified Eagle's medium (DMEM)-based assay medium, and phosphate-buffered saline (PBS) solution. These kits are made by MatTek Corporation (Ashland, MA, USA). The human epidermal model consisting of an epidermis with cornified layers was prepared as previously described (Liebsch et al., 2000).

Vitrolife-Skin™ models were supplied from Gunze Corporation Ltd. (Kyoto, Japan) as kits containing 24 models, collagen sponges without cells and sufficient amounts of DMEM-based assay medium, as shown in Fig.3. The human skin model consisting of a dermis and epidermis with cornified layers was prepared as previously described (Morikawa et al., 2002; Morota et al., 1998; Morota et al., 1999).

Materials

A total of 13 test chemicals including a positive control (10 % potassium hydroxide solution) were selected from the chemicals tested in the ECVAM skin corrosive validation study (Fentem et al., 1998, Liebsch et al., 2000). The chemical distributors selected test chemicals considering a balanced representation of the chemical classes, rate of corrosion or non-corrosion, solubility etc. from the total 60 chemicals tested in the ECVAM validation study. Test chemicals included six of which are known to be corrosive *in vivo*, six which are non-corrosive, six liquids, four solids and two powders, excluding the positive control. Each laboratory was sent the rotated 11 chemicals, including the positive control, in 13 test chemicals as shown in Table 2. Therefore, five data items from each laboratory for each chemical were obtained. All blinded test chemicals were treated as powerful drugs or poisons in each laboratory. The management team considered the minimum appropriate number of chemicals for catch up validation.

All test chemicals used were from the same batch and were purchased from Sigma Aldrich (Milwaukee, USA) and Wako Pure Chemical Industries, Ltd. (Osaka, Japan) and were supplied to each laboratory by the chemical distributors. Phosphate-buffered saline (PBS) and isopropanol were obtained from Wako Pure Chemical Industries,

Table 1 List of members in skin corrosivity validation assay

Japanese Society for Alternative to Animal Experiments Validation Executive Committee

	Organization	Name
Chairman	Tokyo University of Science, Faculty of Engineering, Dept. Management Science	Isao Yoshimura
	National Institute of Health Science, Biological Safety Research Center, Division of Pharmacology	Yasuo Ohno

Study Director

	Organization	Name
	National Institute of Health Sciences, Biological Safety Research Center, Division of Toxicology	Tomoko Ando
	Nihon Nohyaku Co., Ltd., Research Division, Toxicological & Pharmaceutical Research Center	Katsuhiko Inagaki
	Nippon Soda Co., Ltd., Odawara Research Center, Toxicological Research Department	Mami Kuboki
	Nippon Menard Cosmetic Co., Ltd., Research Laboratories	Hajime Kojima
	Sumitomo Chemical Co., Ltd., Environmental Health Science Laboratory, Biochemistry Group	Yosuke Nakamura
	The Institute of Environmental Toxicology, Toxicology Division II, Laboratory of Immunotoxicology	Tadashi Kosaka

Kit supplier

	Organization	Name
	Kurabo Industries Ltd., Bio-medical Department	Hisashi Torishima
	Kurabo Industries Ltd., Biomedical Department	Michiru Genno
	Gunze Limited, Division of Research & Development	Noriyuki Morikawa

Coordinator

	Organization	Name
	Sumitomo Chemical Co., Ltd., Environmental Health Science Laboratory, Biochemistry Group	Naohiko Isobe
	Nippon Soda Co., Ltd., Agro Product Division, Regulatory Affairs Group	Yukihiro Kanaguchi
	National Institute of Health Sciences, Biological Safety Research Center, Division of Toxicology	Jun Kanno
	The Institute of Environmental Toxicology, Toxicology Division II	Takanori Harada
	Nihon Nohyaku Co., Ltd., Research Division, Toxicological & Pharmaceutical Research Center	Masaru Nogata
	Nippon Soda Co., Ltd., Agro Product Division, Regulatory Affairs Group	Mitsuo Hattori
	Nippon Soda Co., Ltd., Odawara Research Center, Toxicological Research Department	Yoshinobu Fujii
	The Institute of Environmental Toxicology, Toxicology Division II, Laboratory of Neurotoxicology	Sayaka Ishimine
	Sumitomo Chemical Co., Ltd., Environmental Health Science Laboratory, Biochemistry Group	Takashi Morimoto

Ltd. and 3-(4,5-dimethylthiazol-2-yl)- 2,5- di-phenyltetrazolium bromide (MTT) and MTT formazan were obtained from Sigma Aldrich. They were supplied by the management team.

Methods

Chemical application procedure according to the ECVAM validation study.

The experimental steps of the method were performed according to the protocol used in phase III of the EpiDerm™ skin corrosivity test (Liebsch et al., 2000) with slight modifications. The EpiDerm™ models were equilibrated at 37°C and 5% CO₂ within one hour after receiving a kit and placed in 1 mL of DMEM-based assay medium in 6-well plates before use. If kept for a few days, it was preserved in a refrigerator. The Vitrolife-Skin™ models were placed in 250 µL of DMEM-based assay medium in 24-well plates and equilibrated for several hours' incubation (37°C, 5% CO₂) within a few days after receiving a kit. One hour before dosing, the models were transferred in 1 mL of DMEM-based assay medium to 6-well plates. Test chemicals were applied directly to the stratum corneum of two replicate models per chemical. Liquids (50 µL) were applied using a positive displacement pipette. Solids were crushed to a powder, if necessary, and 25 mg was applied using a spatula with the addition of 25µL of dis-

tilled water to ensure good contact with the surface. Two models were dosed with 100 µL distilled water as a negative control. After exposure for three or 60 min. at room temperature (15-25°C), two replicate models for each exposure time were rinsed thoroughly with PBS to remove the test chemical from the surface.

Calculation of cell viability

The effects of the test chemicals on cell viability were determined using an MTT reduction assay. After blotting, the models were incubated in 0.3 mL (EpiDerm™) or 1 mL (Vitrolife-Skin™) of each DMEM-based assay medium containing 0.5 mg of MTT for an additional three hours at 37°C and 5% CO₂. Living cells were dyed dark-violet by the MTT reagents. After the models were washed with PBS, biopsies of Vitrolife-Skin™ models were taken using a biopsy punch (6 mm diameter), although this operation is not used in EpiDerm™ models. The biopsies were separated from the models using forceps, and placed into acidified isopropanol (2.0mL: EpiDerm™, 1.0 mL: Vitrolife-Skin™), after removing excess water by placing the samples on absorbent paper. Precipitated formazan was extracted overnight at room temperature with protection from light. The absorbance of the extracts was measured at 570 nm using a UV-VIS spectrophotometer. Adequate absorbance of spectrophotometers was checked using 0.1mg/mL solution of MTT formazan prior to the validation study. Cell viability of EpiDerm™ models determined by the MTT reduction assay method was expressed as follows:

$$\text{Cell viability} = \frac{A_t}{A_c} \times 100 (\%), \quad (1)$$

where *A_t* and *A_c* are the absorbancies of the extracts when test chemicals and a negative control, respectively, are applied to the cultured skin model.

In case of Vitrolife-Skin™, additional tests using collagen sponges without cells were performed, with the potential to interfere with the MTT assay, and thus cell viability was expressed as follows:

$$\text{Cell viability} = \left(\frac{A_t - A_{bt}}{A_c - A_{bc}} \right) \times 100 (\%), \quad (2)$$

where *A_t* and *A_c* are absorbancies of the extracts

Table 2 Test chemicals

No.	Name	C/NC	Comments
1	Potassium hydroxide(10%aq)	C	Positive control
2	Sulfuric acid(10% wt)	C	
3	Octanoic (Caprylic) acid	C	
4	Sodium hydroxide(4.88%)	C	
5	Phenol	C	
6	Chromium trioxide	C	
7	Phosphoric acid	C	
8	Sodium perborate	NC	
9	Tetrachloroethylene	NC	
10	Potassium hydroxide(5% aq)	NC	
11	4-Amino-1,2,4-triazole	NC	
12	L-Lactic acid	NC	
13	Isopropanol (2-propanol)	NC	

when test chemicals and a negative control, respectively, are applied to the viable Vitro-life-Skin™ model, and A_{bt} and A_{bc} are the values obtained for a blank test using a test chemical and the negative control, respectively, with a collagen sponge without cells.

Prediction models

Predictions of *in vitro* corrosiveness/non-corrosiveness were made according to the refined final prediction model (PM2) used in phase III of the EpiDerm™ skin corrosivity test (Liebsch et al., 2000). Hence, chemicals that reduced cell viability to less than 50% upon exposure to the Vitro-life-Skin™ model for three min. were predicted to

be ‘corrosive’ *in vivo*. If 3 min. exposure produced cell viability of $\geq 50\%$, the chemical was classified as ‘non-corrosive’ after a 3 min. exposure, but the same chemical was still be classified as ‘corrosive’ if viability after a 60 min. exposure was below 15%. The results obtained using the EpiDerm™ and Vitro-life-Skin™ models in this study were compared with the results of ECVAM validation studies using EpiDerm™ (Liebsch et al., 2000) and EPISKIN™ (Fentem et al., 1998) for skin corrosivity testing.

This test was repeated twice. If different results from the two tests were obtained, a third test was performed at each laboratory and used for final judgment.

Table 3 Data from each laboratory

Chemical Lab.	Potassium hydroxide (10%) Corrosive						Sulfuric acid (10%) Corrosive					Tetrachloroethylene Non-Corro				
	NIHS	NN	NS	NM	SC	IET	NIHS	NN	NS	NM	SC	NIHS	NN	NS	NM	IET
Blind No.	1	2	3	4	5	6	13	14	15	16	17	18	19	20	21	22
EpiDerm -test 1-	C	C	C	C	C	C	NC	NC	NC	C	C	NC	NC	NC	NC	NC
EpiDerm -test 2-	C	C	C	C	C	C	NC	C	C	C	C	NC	NC	NC	NC	NC
EpiDerm re-trial	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
Judge	C	C	C	C	C	C	NC	C	C	C	C	NC	NC	NC	NC	NC
Vitro-life-Skin -	C	C	C	C	C	C	C	C	C	C	C	NC	NC	NC	NC	NC
Vitro-life-Skin -	C	C	C	C	C	C	C	C	NC	C	C	NC	NC	NC	NC	NC
Vitro-life-Skin re-	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
Judge	C	C	C	C	C	C	C	C	C	C	C	NC	NC	NC	NC	NC

Chemical Lab.	Octanoic acid Corrosive					Potassium hydroxide(5%) Non-					Sodium hydroxide(4.88%) Corrosive				
	NIHS	NN	NS	NM	IET	NIHS	NN	NS	SC	IET	NIHS	NN	NS	SC	IET
Blind No.	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37
EpiDerm -test 1-	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
EpiDerm -test 2-	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
EpiDerm re-trial	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
Judge	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
Vitro-life-Skin -	C	C	NC	C	C	C	C	C	C	C	C	NC	C	C	C
Vitro-life-Skin -	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
Vitro-life-Skin re-	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
Judge	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C

Chemical Lab.	4-Amino-1,2,4-triazole Non-Corro.					Phosphoric acid Corrosive					L-Lactic acid Non-Corro.				
	NIHS	NN	NM	SC	IET	NN	NS	NM	SC	IET	NIHS	NS	NM	SC	IET
Blind No.	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52
EpiDerm -test 1-	NC	NC	NC	NC	NC	C	C	C	C	C	NC	C	C	NC	C
EpiDerm -test 2-	NC	NC	NC	NC	NC	C	C	C	C	C	C	C	C	C	C
EpiDerm re-trial	NC	NC	NC	NC	NC	C	C	C	C	C	C	C	C	C	C
Judge	NC	NC	NC	NC	NC	C	C	C	C	C	C	C	C	C	C
Vitro-life-Skin -	NC	NC	NC	NC	NC	C	C	C	C	C	C	C	C	C	C
Vitro-life-Skin -	NC	NC	NC	NC	NC	C	C	C	C	C	C	C	C	C	C
Vitro-life-Skin re-	NC	NC	NC	NC	NC	C	C	C	C	C	C	C	C	C	C
Judge	NC	NC	NC	NC	NC	C	C	C	C	C	C	C	C	C	C

Chemical Lab.	Isopropanol Non-Corro.					Phenol Corrosive					Sodium perborate Non-Corro.					Chromium trioxide Corrosive				
	NN	NS	NM	SC	IET	NIHS	NN	NM	SC	IET	NIHS	NN	NS	NM	SC	NIHS	NS	NM	SC	IET
Blind No.	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72
EpiDerm -test 1-	NC	NC	NC	NC	NC	C	C	C	C	C	NC	NC	NC	NC	NC	C	C	C	C	C
EpiDerm -test 2-	NC	NC	NC	NC	NC	C	C	C	C	C	NC	NC	NC	NC	NC	C	C	C	C	C
EpiDerm re-trial	NC	NC	NC	NC	NC	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
Judge	NC	NC	NC	NC	NC	C	C	C	C	C	NC	NC	NC	NC	NC	C	C	C	C	C
Vitro-life-Skin -	NC	NC	NC	NC	NC	C	C	C	C	C	NC	NC	NC	NC	NC	C	C	C	C	C
Vitro-life-Skin -	NC	NC	NC	NC	NC	C	C	C	C	C	NC	NC	NC	NC	NC	C	C	C	C	C
Vitro-life-Skin re-	NC	NC	NC	NC	NC	C	C	C	C	C	NC	NC	NC	NC	NC	C	C	C	C	C
Judge	NC	NC	NC	NC	NC	C	C	C	C	C	NC	NC	NC	NC	NC	C	C	C	C	C

Laboratory:

NIHS: Div. Toxicol., NIHS
 NS: ODAWARA Res. Center, Nippon Soda Co., Ltd.
 SC: Environmental Health Science Lab., Sumitomo Chemical Co., Ltd.

NN: Res. Div., Nihon Nohyaku Co., Ltd.
 NM: Res. Lab., Nippon Menard Cosmetic Co., Ltd.
 IET: Toxicol. Div., The Inst.Environmental Toxicol.

C: Corrosive, NC: Non-Corrosive

Results

This validation study was not performed under GLP. However, all data obtained in each laboratory followed GLP compliance and spirit. Their records (data and detailed documents) could be checked after the assays, and raw data was sent to Tokyo Univ. of Science for analysis by biostatisticians. All documents were checked by the chairperson, biostatisticians and chemical distributors, and are stored in the NIHS.

Predictivity

Using cell viability after exposure to test chemicals for three or 60 min., the chemical classifications

according to the EpiDerm™ prediction model are shown in Table 3. Data for positive controls in the two models were evaluated correctly at all laboratories. The EpiDerm™ data summarized in Table 4 excluded the positive control data. Of 30 classifications of six chemicals in the corrosive class, 29 classifications of EpiDerm™ were correctly predicted to be corrosive, and sensitivity was 96.7%. All six chemicals in the corrosive class were correctly predicted excluding one laboratory. Lab.1 gave a negative classification of sulfuric acid from two data sets, but this chemical is corrosive. Cell viability values after exposure to sulfuric acid for 60 min. were 18.54% and 38.80%, and these values

Table 4 Contingency table for EpiDerm™ predictions

<i>Vitro</i> <i>Vivo</i>	Corrosive	Non-Corrosive
Corrosive	29	1
Non-Corrosive	10 (5% KOH, Lactic Acid)	20

Table 5 Contingency table for Vitrolife-Skin™ predictions

<i>Vitro</i> <i>Vivo</i>	Corrosive	Non-Corrosive
Corrosive	30	0
Non-Corrosive	10 (5% KOH, Lactic Acid)	20

Table 6 Key statistical parameters for the four tests

	EpiDerm™	Vitrolife-Skin™	EpiDerm™ (ECVAM)	EPISKIN™ (ECVAM)
No. of Chemicals	12	12	24	60
Sensitivity	100% (12/12)	100% (12/12)	92%	82%
Specificity	66.7% (4/6)	66.7% (4/6)	83%	84%
Accuracy	83.3% (10/12)	83.3% (10/12)	92%	83%
False positive rate	16.7% (2/12)	16.7% (2/12)	17%	19%
False negative rate	0% (0/12)	0% (0/12)	8%	14%

were slightly high compared to 15%, which is the border line. On the other hand, of 30 classification of six chemicals in the non-corrosive class, 20 classifications of EpiDerm™ were correctly predicted to be non-corrosive, and specificity was 66.7%, but two were false positives. There were 5% potassium hydroxide and lactic acid. All the laboratories gave them positive classifications from two data sets, which is a non-corrosive chemical. Positive predictivity was 74.4% (29 true corrosive classifications / 39 corrosive classifications in this assay). Negative predictivity was 95.2% (20 true non-corrosive classifications / 21 non-corrosive classifications in this assay). The total consistency rate was 81.7% (49 true classifications / 60 classifications in this assay).

The Vitrolife-Skin™ data are summarized in Table 5, excluding the positive control data. Of 30 classifications of six chemicals in the corrosive class, 30 of Vitrolife-Skin™ were correctly predicted to be corrosive, and sensitivity was 100%. All six chemicals in the corrosive class were correctly predicted.

On the other hand, of 30 classification of six chemicals in the non-corrosive class, 20 of Vitrolife-Skin™ were correctly predicted to be non-corrosive, and specificity was 66.7%, but two were false positives. They were 5% potassium hydroxide and lactic acid, which all laboratories gave a positive classification from two data sets. This chemical is non-corrosive. Positive predictivity was 75% (30 true corrosive classifications / 40 corrosive classifications in this assay). Negative predictivity was 100% (20 true non-corrosive classifications / 20 non-corrosive classifications in this assay). The total consistency rate was 83.8% (50 true classifications / 60 classifications in this assay).

Predictability of these two models was similar to the results obtained by the ECVAM validation study.

Intralaboratory variation

Most chemicals did not show any great differences in scores on tests repeated at each laboratory. Different classifications of EpiDerm™ accounted for 6.66% (4/60). These data are not shown in the Tables. Cell viabilities of sulfuric acid after exposure for 60 min. in Lab. 2 were 17.26%, 9.46% and 12.02%, and those in Lab.3 were 15.72%, 10.58% and 9.01%, respectively. On the other hand, cell viabilities of lactic acid after exposure for 60 min. in Lab. 1 were 16.55%, 13.39% and 7.19%, while

those in Lab.5 were 15.85%, 12.01% and 15.89%, respectively. These cell viabilities were around 15% after exposure for 60 min. (the success criteria).

Different classifications of Vitrolife-Skin™ accounted for 5.0% (3/60). Cell viabilities of sulfuric acid after exposure for 60 min. in Lab. 3 were 5.90%, 16.09% and 6.34%, while after exposure to octanoic acid for 60 min in Lab.3 were 21.37%, 11.77% and 10.71%. These cell viabilities were around 15% after exposure for 60 min (the success criteria). Meanwhile, cell viabilities of sodium hydroxide (4.88%) after exposure for 3 min. in Lab. 2 were also 55.12%, 15.41% and 17.51%. These cell viabilities were around 50% after exposure for 3 min. (the success criteria).

These cell viabilities were in an extremely narrow range despite the different classifications. Therefore, intralaboratory variation between the two models is presumed to be small.

Interlaboratory variation

In EpiDerm™, inter-laboratory variation was significant for only sulfuric acid. The classification of sulfuric acid in Lab. 1 was different from the data in the other four laboratories. In the data of Lab.1, not shown in the Tables, cell viabilities after exposure for 60 min. were 18.54% and 38.80%, and these values were almost the same as the positive classification. For Vitrolife-Skin™, inter-laboratory variation was not significant. From these results, the feasibility of using EpiDerm™ and Vitrolife-Skin™ was suggested by the experiment.

Discussion

From the obtained data, we confirmed the potential of using EpiDerm™ and Vitrolife-Skin™ as methods to evaluate the corrosivity of a chemical. We consider the data from these models has high predictivity, and low intra- and inter-laboratory variation.

With Vitrolife-Skin™, however, it is necessary to use limited blank data using collagen sponges without cells.

Modified points of Vitrolife-Skin™ from the ECVAM skin corrosivity validation study

Application volume

Although the surface of the Vitrolife-skin™ model (0.5 cm²) is similar to that of EpiDerm™ (0.63cm²), 50 µL of Liquid chemical was often insufficient for the surface. In this study, therefore,

the application volume of liquids was increased from 50 μ L, the volume used in the phase III protocol in the EpiDermTM skin corrosivity test, to 100 μ L. For the same reason, 50 mg of solid chemical was applied and 50 μ L of water was added to ensure good contact with the surface (in contrast to the Phase III protocol, in which 25mg of solid and an additional 25 μ L of water were applied. Additional tests using collagen sponges without cells, the Vitrolife-SkinTM model uses a collagen sponge without cells to construct the dermal layer, and this allows test chemicals to be easily absorbed and bound, compared with epidermal models consisting of only an epidermal layer and supporting material. In a previous study, tests using collagen sponges without cells, instead of non-viable Vitrolife-SkinTM models, were performed for several test chemicals with the potential to interfere with the MTT assay (Mirokawa, 2006). For 3-methoxypropylamine and n-heptylamine, these experiments suggested about 50-60% and 80% "viability", respectively, due to a chemical reaction with the MTT medium. Hence, the 70-80% viability obtained for 3-methoxypropylamine with the Vitrolife-SkinTM model should be corrected to about 20%. In the same way, the 120% viability obtained for n-heptylamine should be decreased to about 40%. Therefore, these two chemicals, which were incorrectly classified as negatives by testing without using blank collagen sponges, should correctly be classified as corrosive by adding blank collagen sponges, in agreement with the results from the EpiDermTM model. The additional test for the other six chemicals gave results of around 15% "viability", such that the Vitrolife-SkinTM *in vitro* prediction of corrosivity was not changed.

Therefore, we obtained blank data using collagen sponges without cells in the validation of Vitrolife-SkinTM. In this validation study, we detected solubilization, swelling and color change after exposure to chemicals, and the need to use blank collagen sponges without cells.

Comparison of skin models

As shown in Table 6, there was no difference in sensitivity, specificity, accuracy, false positive rate or false negative rate between EpiDermTM and Vitrolife-SkinTM in this validation study. The result in this validation study may be due to no difference in structure between a two-layer skin model consisting of a dermis and epidermis (Vitrolife-SkinTM) and epidermal models (EpiDermTM). The barrier

function of cornified layers of the cultured epidermal and skin model is less effective compared with human skin tissue (Kojima et al., 2000). In addition, as chemical exposure times become longer, stronger cytotoxicity occurs due to the accumulation of chemicals which permeate the cornified layer of the skin model. However, it is considered the barrier function of these model is similar.

The sensitivity was 92% in phase III of the EpiDermTM study and 82% in EPISKINTM study, and the present values (100%) were higher than data of these previous validation assays. The specificity, however, was 83% in phase III of the EpiDermTM study and 84% in the EPISKINTM study, and the present ones (66.7%) were lower than those. We consider these accuracy and false positive rates to be no different between the present validation and previous validation study. On the other hand, none of the false negative rates in present validation study were lower than data from previous validation studies. This issue must be handled carefully, because this assay is a catch-up validation trial, and the number of chemicals and classes is small.

Though peer review of these models is in progress, the ad hoc. committee of toxicology at MHLW in Japan has approved the utilization of these models to evaluate the corrosivity of a chemical.

Acknowledgment

This validation was funded by a grant from MHLW.

References

- Botham P.A., Chamberlain M., Barratt M.D., Curren R.D., Esdaile, D.J., Gardner J.R., Gordon, V.C., Hildebrand, B., Lewis, R.W., Liebsch, M., Logemann, P., Osborne, R., Ponc, M., Regnier, J.-F., Steiling, W., Walker, A.P. and Balls, M. (1995) A prevalidation study on *in vitro* skin corrosivity testing: The report and recommendations of ECVAM workshop 6. ATLA 23:219-255.
- Barratt, M.D., Brantom, P.G., Fentem, J.H., Gerner, I., Walker, A.P., and Worth, A.P. (1998) The ECVAM international validation study on *in vitro* tests for skin corrosivity. 1. Selection and distribution of the test chemicals, Toxic. in Vitro, 12, 471-482.
- EC (2000) Annex I to Commission Directive 2000/33/EC of 25 April 2000 adapting to technical progress for the 27th time Council Directive 67/548/EEC on the approximation of laws, regulations and administrative provisions relating to the

classification, packaging and labeling of dangerous substances, Official Journal of the European Communities, L136, 91-97.

Fentem, J.H., Archer, G.E.B., Balls, M., Botham, P.A., Curren, R.D., Earl, L.K., Esdaile, D. J., Holzhütter, H.-G., and Liebsch, M. (1998) The ECVAM international validation study on in vitro tests for skin corrosivity. 2. Results and evaluation by the Management Team, *Toxic.in Vitro*, 12,483-524.

ICCVAM (2002) NIH Publication No.02-4502 ICCVAM evaluation of EPISKIN™, EPIDERM™(EPI-200) and rat skin transcutaneous electrical resistance (TER) assay.

Kojima, H., Katada, T., and Konishi, H. (2000) Which cytotoxicity tests are useful for prediction of skin irritation by surfactants?, *Altern. Animal Test. Experiment*, 6, 79-88.

Liebsch, M., Traue, D., Barrabs, C., Spielmann, H., Uphill, P., Wilkins, S., McPherson, J.P., Wiemann, C., Kaufmann, T., Remmele, M., and Holzhütter, H.-G. (2000) The ECVAM prevalidation study on the use of EpiDerm for skin corrosivity testing, *ATLA*, 28, 371-401.

Morikawa N., Morota, K., Morita, S., Kojima, H., Nakata, S., and Konishi, H. (2002) Prediction of human skin irritancy using a cultured human skin model: comparison of chemical application procedures and development of a novel chemical application procedure using the Vitrolife-Skin™ model, *Altern. Animal Test. Experiment*, 9, 1-10.

Morikawa N., Morota, K., Suzuki, M., Kojima, H., Nakata, S., and Konishi, H. (2005) Experimental study on a novel chemical application procedure for in vitro skin corrosivity testing using the Vitrolife-Skin™ human skin model, *Altern. Animal Test. Experiment*, 11, 68-78.

Morota, K., Morikawa, N., Morita, S., Kojima, H., and Konishi, H. (1998) Development and evaluation of the cultured skin model, *Tiss. Cult. Res. Commun.*, 17, 87-93.

Morota, K., Morikawa N., Morita, S., Kojima, H., and Konishi, H. (1999) Alternative to primary Draize skin irritation test using cultured human skin model: comparison of six end points, *Altern. Animal Test. Experiment*, 6, 41-51.

OECD guideline for the testing of chemicals (2004) Draft proposal for new guideline: 430, *In vitro* skin corrosion: Transcutaneous electrical resistance test (TER).

OECD guideline for the testing of chemicals (2004) Draft proposal for new guideline: 431, *In vitro* skin corrosion: Human skin model test.

(Received: October 24, 2007/

Accepted: January 25, 2008)

Corresponding author:

Hajime Kojima, Ph.D.

Japanese Center for the Validation of Alternative Methods (JaCVAM),

National Institute of Health Sciences (NIHS),

1-18-1, Kamiyoga, Setagaya-ku, Tokyo, 158-8501, Japan

Tel: +81-3-3700-9874

Fax: +81-3-3700-9874

E-mail: h-kojima@nihs.go.jp

JaCVAM: An organization supporting the validation and peer review of new alternatives to animal testing

Hajime Kojima

JaCVAM, NIHS, Japan
1-18-1 Kamiyoga, Setagaya-ku, 158-8501 Tokyo, Japan
h-kojima@nihs.go.jp

Abstract

In November 2005, the Japanese Center for the Validation of Alternative Methods (JaCVAM) was established as part of the Division of Pharmacology at the National Center for Biological Safety and Research, affiliated with the National Institute of Health Sciences (NIHS) in Japan. The key objectives of JaCVAM are: 1) to ensure that new or revised test methods are validated, peer reviewed, and officially accepted by regulatory agencies, and 2) to expand international cooperation on alternatives to animal testing. This paper describes in further detail JaCVAM's current activities and future direction.

Keywords: validation, peer review, alternative, JaCVAM

1. Introduction

In November 2005, the Japanese Center for the Validation of Alternative Methods (JaCVAM) was established as part of the Division of Pharmacology at the National Center for Biological Safety and Research, affiliated with the National Institute of Health Sciences (NIHS) in Japan. One mission of JaCVAM is to promote practice of the 3Rs (Reduction, Refinement and Replacement) in the area of animal testing, with Reduction and Replacement prioritized in Japan. Key objectives of JaCVAM are: 1) to ensure that new or revised test methods are validated, peer reviewed, and officially accepted by the regulatory agencies, and 2) to expand international cooperation on alternatives to animal testing. The main activities of JaCVAM will focus on the following missions and objectives: 1) coordination of peer review and regulatory acceptance of new and revised test methods; 2) support of validation work for new and revised test methods; and 3) promotion of the 3Rs and 4) working to promote international partnership surrounding the issue of alternative methods.

2. Organization of JaCVAM and supporting groups

JaCVAM has five members: a director, Dr. Hajime Kojima; a visiting researcher, Dr. Mitsuteru Masuda; a researcher, Miss Shoko Arai; and two secretaries. Though JaCVAM is a small organization, it is supported by several groups, as shown in Fig. 1. Firstly, JaCVAM has its own steering committee, which is in charge of JaCVAM activities. This committee is comprised of six members: Dr. Toru

Inoue (Chair: Director of the National Center for Biological Safety and Research in NIHS), Dr. Yasuo Ohno (Vice President of NIHS, and a founder of JaCVAM), Dr. Kenichi Nakazawa (Head of the Division of Pharmacology), Dr. Mitsuteru Masuda (JaCVAM), Dr. Hiroshi Itagaki (Shiseido Co., Ltd., President of Japanese Society for Alternative to Animal Experiments: JSAAE) and Dr. Hajime Kojima (JaCVAM).

The roles of the JaCVAM steering committee are:

- ◆ To prepare the validation or peer review process of new or revised test methods.
- ◆ To evaluate international cooperation.
- ◆ To select advisory board members.
- ◆ To select peer review panel members.
- ◆ To select regulatory acceptance board members.
- ◆ To consult with NIHS support members.
- ◆ To check JaCVAM plans and reports.

Secondly, JaCVAM (and its steering committee) have an advisory board which monitors its activities. This board is comprised of eight members, including one dermatologist and other individuals belonging to the Japanese Society of Toxicology (JST), the Japanese Association for Laboratory Animal Science, the Japanese Society for Alternative Animal Experiments (JSAAE), the Japanese Pharmaceutical Manufacturers Association (JPMA), the Japanese Cosmetic Industry Association (JCIA), the Ministry of Health, Labour and Welfare (MHLW), and the Animal Welfare Network. These members are reelected every two years. The meeting of the advisory board is held at NIHS twice per year. JaCVAM reports on its activities




Fig. 1. Organization of JaCVAM




Fig. 2. NIHS Support System

and future programs to board members, and in return receives advice on JaCVAM's methods of operation.

Thirdly, JaCVAM is supported financially by the MHLW. The specific source of funding for JaCVAM's development and validation of alternative methods is the MHLW's Government Pension Investment Fund.

Finally, many laboratories at the NIHS, as shown in Fig. 2, assist the JaCVAM with scientific consultations. NIHS conducts research on the quality, safety, and efficacy of pharmaceutical products, foods, and chemicals in the environment. JaCVAM benefits from the large number of specialists working at the NIHS.

3. Organization for validation studies

In Japan, new or revised test methods that are recommended by domestic researchers or developers are validated by an applied science society like the JSAAE, the Japanese Environmental Mutagen Society (JEMS), or the Japanese Society for Dermatoallergology and Contact Dermatitis (JSDCD). A Validation Management Team, which consists of researcher of a particular toxicity, a specialist on validation studies, a biostatistician, and a study manager from each participating laboratory, validates the repeatability and reliability of the new or revised




Fig. 3. Framework for Validating Alternative Methods

method according to OECD Guidance No.34 (OECD,2005) and the National Institute Health (NIH) report (ICCVAM, 1997). JaCVAM participates in this process as a specialist in validation studies, and is responsible for selecting participating laboratories, managing test materials (initial selection, blinding of test substances, and distribution to each laboratory), managing data (data sheet preparation and data collection) and providing financial support. The above details are illustrated graphically in Fig. 3.

4. Organization for peer review and regulatory acceptance

As shown in Fig. 4, JaCVAM has a framework for peer review and regulatory acceptance of alternative methods. After JaCVAM has received a request for peer review from a researcher or developer, the JaCVAM steering committee meets to deliberate on the proposal methods; this should take no longer than three months. Upon the receipt of permission for peer review, JaCVAM organizes the oversight committee in order to evaluate a new test method. The roles of this ad hoc committee are to collect references on the toxicity involved in a new test method, to prepare a draft report, to propose a new validation study, and to provide advice on further research related to the proposed test method. Based on the report and




Fig. 4. Framework for Peer Review and Regulatory Acceptance of Alternative Methods